Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5965 in PNH patients with anemia despite anti-C5 antibody treatment
NCT06715943Phase 3Completed
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-5965 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Chengdu Suncadia Pharmaceuticals. Started Jan 2025; status: completed.
02
Drugs
HRS-5965
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06715943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715943.